Mindwalk Holdings Corp. · NASDAQ:HYFT
Mindwalk — ImmunoPrecise Antibodies — Q1 2025 Earnings Presentation
11 slides from Mindwalk's earnings presentation, Sep 16, 2024
Slide 1: FY 2025 Q1 Earnings Presentation
FY 2025 Q1 Earnings Presentation September 16, 2024 | ir.ipatherapeutics.com | NASDAQ: IPA Presented by Dr. Jennifer Bath, IPA CEO
Slide 2: Disclosures
Disclosures Disclaimer This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilitie
Slide 3: Fiscal Year 2025 Q1 Business Update
Fiscal Year Q1 2025 Earnings Call Fiscal Year 2025 Q1 Business Update ir.ipatherapeutics.com | NASDAQ:IPA ©2024 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a tra demark of ImmunoPrecise Antibodies LTD. BioStrand is a n independently operating s ubsidiary of IPA. BioStrand and LENSai ar
Slide 4: AI-Enhanced Antibody Drug Discovery
Fiscal Year Q1 2025 Earnings Call AI-Enhanced Antibody Drug Discovery Business Model Pillar 1: Pillar 2: Revenue based Licensing based LENSai Data Analytics SaaS/API Revenue Assets, Collaborations and Partnerships (Milestones and Drug Discovery & Development Royalties) Fee-for-Service Revenue Compet
Slide 5: Strategically built for innovation
Fiscal Year Q1 2025 Earnings Call Strategically built for innovation Continued strong financial performance through advanced technology and deep experience Drug Discovery & LENSai Data Assets, Development Analytics SaaS/API Collaborations and Fee-for-Service Partnerships Revenue driver: Technology d
Slide 6: Fiscal Year 2025 Q1 Financial Update
Fiscal Year Q1 2025 Earnings Call Fiscal Year 2025 Q1 Financial Update ir.ipatherapeutics.com | NASDAQ:IPA ©2024 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a tra demark of ImmunoPrecise Antibodies LTD. BioStrand is a n independently operating s ubsidiary of IPA. BioStrand and LENSai a
Slide 7: Quarterly Revenue
Fiscal Year 2025 Q1 Earnings Call Quarterly Revenue $7,0 M $6,5 M $6,2 M $6,2 M $6,0 M $5,7 M $5,6 M $5,3 M $5,2 M $5,2 M $5,2 M $4,7 M $4,8 M $5,0 M $4,7 M $4,6 M $4,0 M $3,0 M $2,0 M $1,0 M $0,0 M Q1 Q2 Q3 Q4 FY25 FY24 FY23 FY22 Al l values listed i n CAD. ir.ipatherapeutics.com | NASDAQ:IPA ©2024
Slide 8: Focus on Efficient Cost Management
Fiscal Year 2025 Q1 Earnings Call Focus on Efficient Cost Management Research & Development Sales & Marketing General & Administrative $5,0 M $1,6 M $1,2 M $1,1 M $4,2 M $4,0 M $1,5 M $4,0 M $0,7 M $0,9 M $0,8 M $3,0 M $1,0 M $2,0 M $0,4 M $0,5 M $1,0 M $0,0 M $0,0 M $0,0 M Q1'25 Q1'24 Q1'25 Q1'24 Q
Slide 9: Net Loss of $4M, equivalent to ($0.15) per share (basic & diluted)
Fiscal Year 2025 Q1 Earnings Call Net Loss of $4M, equivalent to ($0.15) per share (basic & diluted) Net Loss Earnings Per Share $0,0 M 0,00 -$1,0 M -0,05 -$3,4 M -0,14 -$2,0 M -$4,0 M -0,15 -0,10 -$3,0 M -$4,0 M -0,15 Q1 '25 Q1 '24 Q1 '25 Q1 '24 Al l values listed i n CAD. ir.ipatherapeutics.com |
Slide 10: Ending Q1 Cash Balance of $4M
Fiscal Year 2025 Q1 Earnings Call Ending Q1 Cash Balance of $4M July 31, 2024 $4,0 M April 30, 2024 $3,5 M Q1 '25 $3,1 M $0,6 M -$0,3 M -$2,2 M Ops Burn Capex & LHI Financing Total Cash Used Al l values listed i n CAD. ir.ipatherapeutics.com | NASDAQ:IPA ©2024 ImmunoPrecise Antibodies LTD. All right
Slide 11: Q&A Q1 FY 2025 Earnings Call
Q&A Q1 FY 2025 Earnings Call The HUB of September 16, 2024 | ir.ipatherapeutics.com | NASDAQ: IPA TSXV: IPA Biotherapeutic ©2024 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a tra demark of ImmunoPrecise Antibodies LTD. BioStrand is a n independently operating s ubsidiary of ImmunoPreci
ImmunoPrecise Antibodies — Q1 2025 Earnings Presentation on 6ix